Introduction: Hematological malignancies (HM) are relatively frequent nosological entities within the structure of morbidity by malignant tumors, exhibiting a severe evolution, restrained prognosis and negative socio-...Introduction: Hematological malignancies (HM) are relatively frequent nosological entities within the structure of morbidity by malignant tumors, exhibiting a severe evolution, restrained prognosis and negative socio-economic impact in the advanced stages and phases. Objective: The objective of the study was to identify the epidemiological patterns, and to evaluate the epidemiological trends and disease burden issues of HM in the Republic of Moldova and worldwide. Materials and Methods: The following research methods were used: epidemiological, descriptive statistics, clinico-analytic. The diagnosis was proved in all cases by histopathological, cytological, cytogenetic, molecular and immunophenotyping examinations. The qualitative type researches were performed and enriched by the narrative synthesis of the data. From the specialized international bibliographic sources and official statistics concerning HM. The narrative review of the reference sources was fulfilled in the form of a synthesis. Results: The number of newly diagnosed and followed-up patients with HM at the Institute of Oncology in 2016, 2017, 2018, 2019, 2020 and 2021 amounted respectively to 725, 802, 613, 628, 536 and 528, the incidence (new cases per 100,000 population) being 17.6, 19.5, 14.9, 17.7, 15.1 and 20.3. In 2021 HM constituted 6.2% of all newly-diagnosed cases with malignant tumors in the Republic of Moldova. In the same year Hodgkin lymphoma was diagnosed in 10.04% of cases, non-Hodgkin’s lymphomas—in 31.63%, multiple myeloma and plasma cells neoplasms—in 7.77%, lymphoid leukemias—in 17.42%, myeloid leukemias—in 12.31%, monocytic leukemias—in 0.95%, and other leukemias—in 16.29%. In 2019 the male rate was 51.5%, and the female rate—48.5%. Within 2 years males were 266 (50.4%), females—262 (49.6%). The age of 50 - 79 years prevailed in both genders (males—65%, females—72.5%). The children constituted 4.0% of the newly diagnosed cases, 4.8% of those under the follow-up at the end of the year 2019 and 6.4% of the newly diagnosed cases in 2021. The disease span from the onset to diagnosis ranged between 1 - 24 months and constituted on average 5.63 months, without a significant difference as compared to 2019 (5.76 months). The incidence of HM in Western countries is 14 - 19 new cases per 100,000 population (4% of all cases with malignant tumors). The incidence of non-Hodgkin’s lymphomas increased by 45% between 2006 and 2016, from 319,078 to 461,000 cases. Between 2006 and 2016, the incidence of leukemias increased by 26%, from 37,000,000 to 467,000 cases. Conclusions: The epidemiological study revealed slightly lower morbidity by HM in the Republic of Moldova as compared to the West European countries mainly due to the migration of a workable population. The patients with malignant lymphomas, male gender and age categories of 50 - 79 years proved to be commonly registered epidemiological patterns. The narrative analysis of the literature revealed that patients with HM may experience a considerable disease burden with a negative impact on their employment status, working productivity and annual household income.展开更多
目的了解1990-2019年中国慢性阻塞性肺疾病发病、患病、死亡情况及疾病负担情况,预测2020-2030年中国慢性阻塞性肺疾病发病情况,为评估和制定慢性阻塞性肺疾病相关预防治疗政策和措施提供数据支持。方法利用2019年全球疾病负担研究数据...目的了解1990-2019年中国慢性阻塞性肺疾病发病、患病、死亡情况及疾病负担情况,预测2020-2030年中国慢性阻塞性肺疾病发病情况,为评估和制定慢性阻塞性肺疾病相关预防治疗政策和措施提供数据支持。方法利用2019年全球疾病负担研究数据库(Global burden of disease study,GBD),研究分析1990-2019年中国慢性阻塞性肺疾病的发病、患病、死亡、伤残调整寿命年(DALY)、早死寿命损失年(YLL)、伤残寿命损失年(YLD)等情况。采用贝叶斯-时期-队列分析(BAPC)方法,预测2020-2030年中国慢性阻塞性肺疾病发病率。结果相对于1990年,2019年中国慢性阻塞性肺疾病粗患病率增长35.44%,标化患病率减少27.16%,粗发病率增长38.31%,标化发病率减少28.52%,粗死亡率减少30.59%,标化死亡率减少70.08%。1990-2019年中国人群因慢性阻塞性肺疾病导致的YLL率由3281.48/10万降至862.37/10万,YLD率由330.33/10万降至240.40/10万,DALY率由3611.81/10万降至1102.77/10万。2019年男性慢性阻塞性肺疾病DALY率相比于1990年降低66.56%,女性DALY率相比于1990年降低71.87%。2020-2030年中国慢性阻塞性肺疾病标化发病率预计呈下降趋势,2030年男性标化发病率预计比2020年降低31.97%,女性标化发病率预计比2020年降低27.69%。结论1990-2019年,慢性阻塞性肺疾病对中国人口造成的疾病负担总体呈下降趋势。但从患病情况和死亡情况来看,发病及死亡人数较多,中国慢性阻塞性肺疾病的疾病负担仍处于较高水平。同时预测结果显示,未来10年中国慢性阻塞性肺疾病标化发病率在下降,但是仍处于较高水平,因此进行早筛查、早预防和早治疗,及广泛开展慢阻肺相关知识普及,对于做好COPD疾病管理具有重要意义。展开更多
目的:分析海南省1990至2019年肝癌疾病负担的变化趋势及其危险因素归因情况。方法:根据2019年全球疾病负担(Global Burden of Disease,GBD)研究的海南省数据,利用Joinpoint回归模型分析1990至2019年海南省肝癌发病、死亡、伤残调整寿命...目的:分析海南省1990至2019年肝癌疾病负担的变化趋势及其危险因素归因情况。方法:根据2019年全球疾病负担(Global Burden of Disease,GBD)研究的海南省数据,利用Joinpoint回归模型分析1990至2019年海南省肝癌发病、死亡、伤残调整寿命年(disability-adjusted life year,DALY)的变化趋势,平均年度变化百分比(average annual percentage change,AAPC)用于描述年平均变化趋势,年度变化百分比(annual percentage change,APC)用于描述不同阶段时间变化趋势,归因DALY率用于描述危险因素归因情况。结果:1990至2019年海南省肝癌年龄标化发病率、年龄标化死亡率及年龄标化DALY率均呈下降趋势,分别下降了59.30%、61.21%和64.03%(P<0.001)。1990至2019年海南省40岁以下人群肝癌的年龄标化DALY率均较低,1990年的年龄标化DALY率的峰值出现在55~59岁年龄组,2019年后移至75~79岁年龄组。在1990至2019年期间,吸烟一直是海南省肝癌归因DALY率的主要危险因素,而在2019年,高BMI已经超越了药物使用因素,成为肝癌疾病负担的第三大危险因素。结论:海南省肝癌疾病负担总体呈下降趋势,峰值年龄段后移,吸烟、饮酒和高BMI仍是主要危险因素,应继续加强肝癌的早诊早治及危险因素干预等防控工作。展开更多
目的通过分析中国1990—2019年类风湿性关节炎(rheumatoid arthritis,RA)的疾病负担现状和变化趋势,为我国RA防控提供科学依据。方法从2019全球疾病负担(global burden of disease,GBD)数据获得1990—2019年RA的发病率、患病率、死亡率...目的通过分析中国1990—2019年类风湿性关节炎(rheumatoid arthritis,RA)的疾病负担现状和变化趋势,为我国RA防控提供科学依据。方法从2019全球疾病负担(global burden of disease,GBD)数据获得1990—2019年RA的发病率、患病率、死亡率、伤残调整寿命年(disability adjusted life years,DALYs)等指标,通过四项指标的标化率对比分析中国、美国、日本及全球水平随年份发展的变化趋势。结果2019年,中国RA的发病率、患病率、死亡率、DALYs率及其标化率均为女性高于男性,死亡率随着年龄的增长呈上升的趋势,在95岁以上年龄组达到高峰;发病率、患病率及DALYs率随年龄的增长呈先上升后下降的趋势,分别在60~岁、70~岁、85~岁年龄段达到高峰。1990—2019年,中国RA的发病率、患病率、死亡率、DALYs率指标均呈上升趋势,消除人口年龄构成差异后,中国RA标化发病率和标化患病率呈上升的趋势;中国RA标化死亡率和标化DALYs率呈平稳趋势。2019年中国RA的标化发病率、标化患病率和标化DALYs率低于日本、美国和全球平均水平;2019年标化死亡率高于日本、美国和全球平均水平。结论在过去30年来,中国的RA疾病负担呈上升的趋势,应继续加强RA防控的宣传教育,尤其关注女性中老年人群的预防控制,制定合理政策,进一步减轻中国RA疾病负担。展开更多
文摘Introduction: Hematological malignancies (HM) are relatively frequent nosological entities within the structure of morbidity by malignant tumors, exhibiting a severe evolution, restrained prognosis and negative socio-economic impact in the advanced stages and phases. Objective: The objective of the study was to identify the epidemiological patterns, and to evaluate the epidemiological trends and disease burden issues of HM in the Republic of Moldova and worldwide. Materials and Methods: The following research methods were used: epidemiological, descriptive statistics, clinico-analytic. The diagnosis was proved in all cases by histopathological, cytological, cytogenetic, molecular and immunophenotyping examinations. The qualitative type researches were performed and enriched by the narrative synthesis of the data. From the specialized international bibliographic sources and official statistics concerning HM. The narrative review of the reference sources was fulfilled in the form of a synthesis. Results: The number of newly diagnosed and followed-up patients with HM at the Institute of Oncology in 2016, 2017, 2018, 2019, 2020 and 2021 amounted respectively to 725, 802, 613, 628, 536 and 528, the incidence (new cases per 100,000 population) being 17.6, 19.5, 14.9, 17.7, 15.1 and 20.3. In 2021 HM constituted 6.2% of all newly-diagnosed cases with malignant tumors in the Republic of Moldova. In the same year Hodgkin lymphoma was diagnosed in 10.04% of cases, non-Hodgkin’s lymphomas—in 31.63%, multiple myeloma and plasma cells neoplasms—in 7.77%, lymphoid leukemias—in 17.42%, myeloid leukemias—in 12.31%, monocytic leukemias—in 0.95%, and other leukemias—in 16.29%. In 2019 the male rate was 51.5%, and the female rate—48.5%. Within 2 years males were 266 (50.4%), females—262 (49.6%). The age of 50 - 79 years prevailed in both genders (males—65%, females—72.5%). The children constituted 4.0% of the newly diagnosed cases, 4.8% of those under the follow-up at the end of the year 2019 and 6.4% of the newly diagnosed cases in 2021. The disease span from the onset to diagnosis ranged between 1 - 24 months and constituted on average 5.63 months, without a significant difference as compared to 2019 (5.76 months). The incidence of HM in Western countries is 14 - 19 new cases per 100,000 population (4% of all cases with malignant tumors). The incidence of non-Hodgkin’s lymphomas increased by 45% between 2006 and 2016, from 319,078 to 461,000 cases. Between 2006 and 2016, the incidence of leukemias increased by 26%, from 37,000,000 to 467,000 cases. Conclusions: The epidemiological study revealed slightly lower morbidity by HM in the Republic of Moldova as compared to the West European countries mainly due to the migration of a workable population. The patients with malignant lymphomas, male gender and age categories of 50 - 79 years proved to be commonly registered epidemiological patterns. The narrative analysis of the literature revealed that patients with HM may experience a considerable disease burden with a negative impact on their employment status, working productivity and annual household income.
文摘目的了解1990-2019年中国慢性阻塞性肺疾病发病、患病、死亡情况及疾病负担情况,预测2020-2030年中国慢性阻塞性肺疾病发病情况,为评估和制定慢性阻塞性肺疾病相关预防治疗政策和措施提供数据支持。方法利用2019年全球疾病负担研究数据库(Global burden of disease study,GBD),研究分析1990-2019年中国慢性阻塞性肺疾病的发病、患病、死亡、伤残调整寿命年(DALY)、早死寿命损失年(YLL)、伤残寿命损失年(YLD)等情况。采用贝叶斯-时期-队列分析(BAPC)方法,预测2020-2030年中国慢性阻塞性肺疾病发病率。结果相对于1990年,2019年中国慢性阻塞性肺疾病粗患病率增长35.44%,标化患病率减少27.16%,粗发病率增长38.31%,标化发病率减少28.52%,粗死亡率减少30.59%,标化死亡率减少70.08%。1990-2019年中国人群因慢性阻塞性肺疾病导致的YLL率由3281.48/10万降至862.37/10万,YLD率由330.33/10万降至240.40/10万,DALY率由3611.81/10万降至1102.77/10万。2019年男性慢性阻塞性肺疾病DALY率相比于1990年降低66.56%,女性DALY率相比于1990年降低71.87%。2020-2030年中国慢性阻塞性肺疾病标化发病率预计呈下降趋势,2030年男性标化发病率预计比2020年降低31.97%,女性标化发病率预计比2020年降低27.69%。结论1990-2019年,慢性阻塞性肺疾病对中国人口造成的疾病负担总体呈下降趋势。但从患病情况和死亡情况来看,发病及死亡人数较多,中国慢性阻塞性肺疾病的疾病负担仍处于较高水平。同时预测结果显示,未来10年中国慢性阻塞性肺疾病标化发病率在下降,但是仍处于较高水平,因此进行早筛查、早预防和早治疗,及广泛开展慢阻肺相关知识普及,对于做好COPD疾病管理具有重要意义。
文摘目的通过分析中国1990—2019年类风湿性关节炎(rheumatoid arthritis,RA)的疾病负担现状和变化趋势,为我国RA防控提供科学依据。方法从2019全球疾病负担(global burden of disease,GBD)数据获得1990—2019年RA的发病率、患病率、死亡率、伤残调整寿命年(disability adjusted life years,DALYs)等指标,通过四项指标的标化率对比分析中国、美国、日本及全球水平随年份发展的变化趋势。结果2019年,中国RA的发病率、患病率、死亡率、DALYs率及其标化率均为女性高于男性,死亡率随着年龄的增长呈上升的趋势,在95岁以上年龄组达到高峰;发病率、患病率及DALYs率随年龄的增长呈先上升后下降的趋势,分别在60~岁、70~岁、85~岁年龄段达到高峰。1990—2019年,中国RA的发病率、患病率、死亡率、DALYs率指标均呈上升趋势,消除人口年龄构成差异后,中国RA标化发病率和标化患病率呈上升的趋势;中国RA标化死亡率和标化DALYs率呈平稳趋势。2019年中国RA的标化发病率、标化患病率和标化DALYs率低于日本、美国和全球平均水平;2019年标化死亡率高于日本、美国和全球平均水平。结论在过去30年来,中国的RA疾病负担呈上升的趋势,应继续加强RA防控的宣传教育,尤其关注女性中老年人群的预防控制,制定合理政策,进一步减轻中国RA疾病负担。
